California Senate Bill 1012, also known as the Regulated Psychedelic Facilitators Act, was introduced earlier this year to allow the therapeutic use of psychedelic substances, including dimethyltryptamine (DMT), mescaline, 3,4-methylenedioxymethamphetamine (MDMA), ibogaine, and psilocybin for adults aged 21 and older. Sponsored by Senator Scott Wiener, this bipartisan bill aimed to ensure safe, regulated access to these therapies by mandating that trained facilitators oversee their use. As exemplified by the recent rescheduling of cannabis and the growing recognition of the therapeutic benefits of psychoactive substances, there appears to be an increasing acceptance of psychedelics for mental health treatment. However, the ultimate fate of SB 1012 suggests that widespread acceptance may still be a work in progress, with change being more like one step back, two steps forward.
The bill proposed establishing a licensing board to develop guidelines for the education and ethical standards of facilitators and emphasized public education, harm reduction, and first responder training to prevent misuse and adverse effects. SB 1012 also sought to make psychedelic-assisted therapy accessible and affordable, addressing the mental health needs of diverse populations, including veterans and first responders. These groups could significantly benefit from alternative treatments for conditions like PTSD, depression, and addiction, becuase studies have shown that they often resist conventional therapies.
Despite progressing through several committees, SB 1012 ultimately stalled out in the Senate Appropriations Committee. The primary obstacle was the potential financial impact, with significant costs estimated for establishing and maintaining the regulatory board. Given California's budget deficit, the Senate Appropriations Committee placed the bill on the "suspense file," a legislative process where bills with substantial costs are often shelved. Consequently, SB 1012 did not progress further and effectively died in committee.
Despite efforts to appeal to Governor Gavin Newsom, who had vetoed a similar bill last year, the fiscal impact and California’s budget deficit proved insurmountable at this time. This setback highlights the challenges of advancing psychedelic policy reform amidst financial constraints. However, Senator Scott Wiener remains dedicated and vows to continue pushing for expanded access to psychedelics for mental health treatment, emphasizing the importance of regulated access.
SACRAMENTO – Senator Scott Wiener released the following statement after SB 1012 was held in the Senate Appropriations Committee:
“We’ve been working for four years to legalize access to psychedelics in California, to bring these substances out of the shadows and into the sunlight, and to improve safety and education around their use,” said Senator Wiener. “We’re in a terrible budget year, where all bills with significant costs are at risk. Nevertheless, it’s disappointing for this bill not to move forward. Psychedelics have massive promise in helping people heal and get their lives back on track. It makes enormous sense for California to lead in creating regulated access under the supervision of a licensed professional. I’m highly committed to this issue, and we’ll continue to work on expanding access to psychedelics.”
Integrating psychedelic therapies into mainstream healthcare is a complex endeavor that faces numerous challenges. However, the future holds promise for expanding access to these substances for therapeutic mental health treatment. Currently, ketamine therapy is one of the only legal options for those seeking healing through a psychedelic experience. Nevertheless, as perceptions shift and more research is conducted, it is likely that other psychedelic therapies will become available.
About the Author
Dr. Ray Rivas, a former general and trauma surgeon with over a decade of experience utilizing ketamine, became a ketamine therapy specialist to treat mental health and pain after witnessing its profound impact on his hospital trauma patients and his own mental health. As the founder and medical director of Innerbloom Ketamine Therapy in San Luis Obispo, California, Dr. Rivas applies his extensive medical expertise to provide safe, evidence-based ketamine treatments for mood disorders, including depression, anxiety, PTSD, and chronic pain. His passion lies in helping patients find relief and rediscover hope through personalized, compassionate care.
Disclaimer: All content on this website, including (but not limited to) this statement, news, blog post, article, testimonial, or FAQ is not medical advice and should not be considered as such. This website cannot diagnose or treat any medical condition. Only a licensed medical professional who is familiar with you and your medical history can do that. Therefore, we cannot be responsible or liable for any actions taken by those who access our website or rely on its content. Please refer to the Terms & Conditions for more information.